Blog
Advancing AD Trials: Integrating Plasma Biomarkers and Imaging for Precision Enrolment
The development of blood-based biomarkers (BBMs) for early detection of Alzheimer’s disease (AD) pathology is transformative for research and drug development. Historically, diagnosis relied on symptomatic presentation with costly confirmatory imaging. Today, the field is shifting toward a biologically defined framework for earlier detection and trial stratification.
Harnessing Neuroimaging in Parkinson’s Disease Clinical Trials: Best Practices and Emerging Standards
As clinical research in Parkinson’s Disease (PD) continues to evolve, neuroimaging has become a cornerstone in trial design, patient selection, and therapeutic evaluation. Across the industry, sponsors and imaging partners are adopting increasingly sophisticated imaging strategies to enhance data quality, regulatory compliance, and scientific insight.
Why Partnerships are the Promising Pathway for Alzheimer’s Breakthroughs
Why Partnerships are the Promising Pathway for Alzheimer’s Breakthroughs Strategic collaborations are key to improving the pace and access to research In collaboration with the Global Alzheimer's Platform Foundation Undiagnosed and Overlooked Everyone knows someone impacted by Alzheimer’s disease (AD), as it affects an estimated 55 million people worldwide.
The New Research Developments Driving Precision Care in Parkinson’s Disease
Parkinson’s disease (PD) research is advancing rapidly, driven by innovations in neuroimaging, biomarker science, and therapeutic development. The field is moving beyond symptom management toward biologically grounded strategies for early diagnosis, disease staging, and modification. Biomarker-Driven Staging: The NSD-ISS Framework A major shift is underway in how PD is diagnosed and staged.
Imaging of Neurodegeneration within the NIA-AA Research Framework: The ‘N’ in the AT(N) Scheme
Imaging of Neurodegeneration within the NIA-AA Research Framework: The ‘N’ in the AT(N) Scheme Alzheimer’s disease (AD) is the most common form of dementia, affecting millions globally. As research shifts increasingly toward earlier diagnosis and targeted interventions, including risk factors, biomarker-based frameworks have become essential tools for guiding both clinical research and drug development.
Biomarkers and imaging in Alzheimer’s disease: Understanding Amyloid and Tau within the ATN Framework
Beta-Amyloid and tau accumulation in Alzheimer’s disease Drug development for Alzheimer’s disease (AD) continues to face significant challenges, largely due to the limited availability of reliable biomarkers and the high risk of trial failure.
A Quick Guide to Imaging Analysis & Operations Essentials in Alzheimer’s Disease Clinical Research
Why is harmonisation of imaging protocols important in Alzheimer's disease clinical trials? Harmonisation of imaging protocols is crucial in Alzheimer's disease clinical trials for several reasons. Firstly, it ensures consistency and accuracy across different trial sites, which is essential for reliable data collection and analysis.
Innovation Trends in AD Research –the shift to increasingly individualised trial design, therapeutics and care.
Innovation Trends in AD Research –the shift to increasingly individualised trial design, therapeutics and care. Alzheimer’s disease (AD) research is entering a new phase of innovation, highlighted by a number of advances presented at recent conferences such as CTAD 2024 in Madrid and AD/PD 2025 in Vienna.
Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis
Imaging: Advancing Biomarker Research for Alzheimer's Disease Diagnosis In an article published in the latest edition of the Journal for Clinical Studies, IXICO’s Chief Scientific Officer Robin Wolz outlines how data from the landmark Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation (GAP) and supported by IXICO as imaging partner, can help better understand the…
Discussing research multi-biomarker advances in Alzheimer’s Disease at ADPD 2025
This week we will be at the ADPD 2025 International Conference talking about some of our latest biomarker research. Specifically, we are presenting an AI-based approach to differentiate different types of dementia from magnetic resonance imaging (MRI).
1-10 of 27 results